These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 9818744

  • 1. Comparative pharmacodynamics of meropenem using an in-vitro model to simulate once, twice and three times daily dosing in humans.
    Bowker KE, Holt HA, Lewis RJ, Reeves DS, MacGowan AP.
    J Antimicrob Chemother; 1998 Oct; 42(4):461-7. PubMed ID: 9818744
    [Abstract] [Full Text] [Related]

  • 2. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
    Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP.
    J Clin Pharmacol; 2003 Oct; 43(10):1116-23. PubMed ID: 14517194
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
    Ikawa K, Nakashima A, Morikawa N, Ikeda K, Murakami Y, Ohge H, Derendorf H, Sueda T.
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5609-15. PubMed ID: 21947393
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection.
    Kongthavonsakul K, Lucksiri A, Eakanunkul S, Roongjang S, Issaranggoon Na Ayuthaya S, Oberdorfer P.
    Int J Antimicrob Agents; 2016 Aug; 48(2):151-7. PubMed ID: 27345269
    [Abstract] [Full Text] [Related]

  • 7. Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy.
    Santos Filho L, Eagye KJ, Kuti JL, Nicolau DP.
    Clin Microbiol Infect; 2007 Jun; 13(6):579-85. PubMed ID: 17331121
    [Abstract] [Full Text] [Related]

  • 8. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y, Kobayashi Y.
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [Abstract] [Full Text] [Related]

  • 9. Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia.
    Jaruratanasirikul S, Limapichat T, Jullangkoon M, Aeinlang N, Ingviya N, Wongpoowarak W.
    Int J Antimicrob Agents; 2011 Sep; 38(3):231-6. PubMed ID: 21726984
    [Abstract] [Full Text] [Related]

  • 10. Relationships between antimicrobial effect and area under the concentration-time curve as a basis for comparison of modes of antibiotic administration: meropenem bolus injections versus continuous infusions.
    Firsov AA, Mattie H.
    Antimicrob Agents Chemother; 1997 Feb; 41(2):352-6. PubMed ID: 9021191
    [Abstract] [Full Text] [Related]

  • 11. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
    Ludwig E, Konkoly-Thege M, Kuti JL, Nicolau DP.
    Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
    [Abstract] [Full Text] [Related]

  • 12. Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic-pharmacodynamic analysis.
    Ohata Y, Tomita Y, Nakayama M, Tamura K, Tanigawara Y.
    J Infect Chemother; 2011 Dec; 17(6):831-41. PubMed ID: 21773752
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin.
    Bowker KE, Wootton M, Rogers CA, Lewis R, Holt HA, MacGowan AP.
    J Antimicrob Chemother; 1999 Nov; 44(5):661-7. PubMed ID: 10552983
    [Abstract] [Full Text] [Related]

  • 15. Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development.
    Tam VH, Ledesma KR, Vo G, Kabbara S, Lim TP, Nikolaou M.
    Antimicrob Agents Chemother; 2008 Nov; 52(11):3987-93. PubMed ID: 18725438
    [Abstract] [Full Text] [Related]

  • 16. Evaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosa.
    Deguchi T, Seike K, Yasuda M, Matsumoto T.
    J Infect Chemother; 2011 Oct; 17(5):726-30. PubMed ID: 21409530
    [Abstract] [Full Text] [Related]

  • 17. The antibacterial activity of meropenem in combination with gentamicin or vancomycin.
    Wise R, Ashby JP, Andrews JM.
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():233-8. PubMed ID: 2509417
    [Abstract] [Full Text] [Related]

  • 18. In vivo and in vitro study of several pharmacodynamic effects of meropenem.
    Fuentes F, Martín MM, Izquierdo J, Gomez-Lus ML, Prieto J.
    Scand J Infect Dis; 1995 Sep; 27(5):469-74. PubMed ID: 8588137
    [Abstract] [Full Text] [Related]

  • 19. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.
    So W, Crandon JL, Hamada Y, Nicolau DP.
    J Antimicrob Chemother; 2016 Feb; 71(2):428-37. PubMed ID: 26559690
    [Abstract] [Full Text] [Related]

  • 20. Experimental verification of the efficacy of optimized two-step infusion therapy with meropenem using an in vitro pharmacodynamic model and Monte Carlo simulation.
    Eguchi K, Kanazawa K, Shimizudani T, Kanemitsu K, Kaku M.
    J Infect Chemother; 2010 Feb; 16(1):1-9. PubMed ID: 20072800
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.